Financial Results, Upcoming Earnings Schedules, New Launches, and Lawsuit Filings - Analyst Notes on AstraZeneca, Boston Scientific, Valeant, Illumina and Mylan

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, May 2, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding AstraZeneca PLC (NYSE: AZN), Boston Scientific Corporation (NYSE: BSX), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Illumina Inc. (NASDAQ: ILMN) and Mylan, Inc. (NASDAQ: MYL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at:

AstraZeneca PLC Analyst Notes
On April 24, 2014, AstraZeneca PLC (AstraZeneca) reported its financial results for Q1 2014. The Company posted 0.49% YoY increase in revenue to $6.4 billion. Core operating margin was down by 5.0 percentage points to 30.4% of revenue, as a result of the increased investment in R&D and growth platforms. Net income for Q1 2014 came in at $527 million, or $0.40 per diluted share, as compared to $828 million, or $0.81 per diluted share, in the prior year period. AstraZeneca attributed decline in net income to the loss on disposal of Alderley Park and the impact of the acquisition of the global diabetes alliance. The Company's core EPS also declined to $1.17 from $1.41 in Q1 2013, mainly due to investment in the key growth platforms and rapidly progressing pipeline. AstraZeneca continues to maintain its guidance at low-to-mid single digit percentage decline in revenues for full-year 2014. The full analyst notes on AstraZeneca are available to download free of charge at:

Boston Scientific Corporation Analyst Notes
On April 29, 2014, Boston Scientific Corporation (Boston Scientific) announced its Q1 2014 financial results. Revenue during the period increased 0.7% YoY to $1.8 billion, but fell short of the Reuters' analyst estimate, sending its stock lower by 6.26% during the same session. Net income for Q1 2014 came in at $133 million, or $0.10 per diluted share, versus net loss of $354 million, or $0.26 per diluted share, in Q1 2013. The adjusted diluted EPS during the quarter increased to $0.20, beating the Reuters' analyst consensus estimate of $0.18. Looking ahead, the Company has raised its full-year 2014 EPS guidance to a range of $0.36 to $0.41 per share from a range of $0.35 to $0.40 announced previously. The Company expects revenue for the full-year 2014 to be in a range of $7.3 to $7.5 billion. The full analyst notes on Boston Scientific are available to download free of charge at:

Valeant Pharmaceuticals International, Inc. Analyst Notes
On April 24, 2014, Valeant Pharmaceuticals International, Inc. (Valeant) announced that it has scheduled a conference call and a live Internet webcast along with a slide presentation on Thursday, May 8, 2014 at 8:00 a.m. ET (5:00 a.m. PT) to discuss its Q1 2014 results. According to Zacks Investment Research, the consensus EPS estimate for Q1 2014 is $1.72. The full analyst notes on Valeant are available to download free of charge at:

Illumina Inc. Analyst Notes
On April 29, 2014, Illumina Inc. (Illumina) announced the introduction of VeriSeqTM PGS, a next-generation sequencing (NGS) solution developed for preimplantation genetic screening (PGS) of embryos using Illumina's NextSeqTM 500 and MiSeq® sequencing systems. According to the Company, the offering brings together the industry-leading Illumina '24sure' array-based platform for PGS with Illumina's next-generation sequencing (NGS) technology providing laboratories a more scalable PGS solution. Tristan Orpin, Senior Vice President and General Manager of Reproductive and Genetic Health for Illumina, said: "VeriSeq PGS demonstrates Illumina's continuing commitment to reproductive and genetic health. By developing and providing accessible tools to perform PGS, we hope to enable reference laboratories to offer these services worldwide." The full analyst notes on Illumina are available to download free of charge at:

Mylan, Inc. Analyst Notes
On April 25, 2014, Mylan, Inc. (Mylan) announced that it has challenged the U.S. Food and Drug Administration (FDA) ruling on generic drug marketing exclusivity on Celecoxib Capsules, the generic version of Pfizer's Celebrex®. Mylan maintains that it is in a position to receive final approval on May 30, 2014, upon expiration of Celebrex's remaining patents. Mylan CEO Heather Bresch, said, "We believe the FDA has made an unprecedented error in this case which clearly caught all industry participants off guard, as evidenced by some who have already settled with Pfizer for December 2014 launch dates, which is post patent expiry." The full analyst notes on Mylan are available to download free of charge at:

About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at]

5. For any urgent concerns or inquiries, please contact us at compliance [at]

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] for consideration.

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Analysts Review